Human Medicines Market Increasingly Supplementing Veterinary Treatment Pipelines

PUNE, India, June 13, 2016 /PRNewswire/ —

The latest research on human medicines market titled “Human Drugs For Veterinary Use – Current Trends and Future Commercial Prospects for Crossover Drugs” says significant unmet needs within veterinary care, including a lack of drugs for senior animals, underdeveloped research in areas such as veterinary oncology, and a scarcity of novel drugs, diagnostic aids, treatment monitoring, and vaccines, are driving veterinarians to treat animals such as dogs, cats and horses by prescribing drugs available in human medicines market.

Complete market report on use of human medicines in veterinary segment spread across 60 pages and talking about 5 established companies in crossover drugs as well as 10 key marketed products is available at .

This research discusses case studies for drugs in the veterinary space human drugs applied in veterinary medicine covering Lysodren (Mitotane) in Dogs, Fluoxetine hydrochloride (Prozac) in Dogs and Cats, Benazepril (Lotensin, Fortekor) in Dogs and Cats as well as Quinidine Sulfate in Horses and Dogs. Key marketed products under Chemotherapy in Dogs and Cats Human Drugs for Veterinary Use covered in this research include Sildenafil, Methimazole, Amlodipine, Phenobarbital, Levothyroxine, cetaminophen, Hydroxyzine, Humulin N, Pentoxifylline and Bethanechol. Key Established Global Players in the Crossover Drugs Market discussed in this 2016 human medicines market report include Zoetis, Boehringer Ingelheim Vetmedica, Merck/MSD Animal Health, Elanco (Eli Lilly) and Merial (Sanofi).

This human medicines market research states that the most significant drivers of Extralabel Drug Use (ELDU) in animals are financial. Unlike the human drugs market, veterinary clinics are involved not only in diagnosis and treatment, but also have the right to dispense pet medications. Consumers cannot purchase the prescribed medications from a pharmacy of their choice, where there would be access to low-priced generic drugs, and human treatments may be a viable alternative.

A blockbuster drug in human health generates revenues in excess of $1 billion, whereas the animal health market’s highest selling drugs achieve $50-100 million, with around 85% of animal sales reaching less than $1 million. In this way, many manufacturers of veterinary drugs are looking for products already licensed for human use to fill their pipelines. Despite these drivers, this new human medicines market research says there are safety, legal, ethical, and health issues associated with ELDU in animals. For instance, prescribing a human drug for veterinary use has its own risks. Mammalian species share many basic similarities in terms of responses to drugs, but there are differences seen at the cellular level, meaning responses may differ.

Another possibility might be that a human drug is prescribed despite the presence of a veterinary-approved alternative due to affordability issues, meaning a veterinarian could face legal issues. Despite such problems, the intersection between human and veterinary medicine is a very important and emerging area that this 2016 human medicines market research believes will receive more focus in the years to come. For example, specially designed clinical trials are currently being run in which pets can be enrolled alongside human patients.

This report on human medicines market provides details of Extra-label Drug Use (ELDU), its application in the veterinary setting and other guidelines and regulations followed by professionals in the animal health industry. It includes insights into the rationale for the transition of several human drugs to the veterinary setting as well as disease overviews, competing treatments, manufacturer information, dosage forms, cost of therapy and marketing information. Order a copy of Human Drugs For Veterinary Use – Current Trends and Future Commercial Prospects for Crossover Drugs market research report on human medicines market at .

Another research available with is Evolving Market Access Strategies – Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets. This report assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. Additionally, the study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support. Read more at .

Explore more reports on pharmaceuticals market at .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune – 411013
Maharashtra, India.
Tel:  +1-888-391-5441

Connect with Us: 
G+ / Google Plus:
RSS / Feeds:

Leave a Reply

Your email address will not be published. Required fields are marked *